VIKRAMTH share price, P/E, ROE & financials

Vikram Thermo (India) (BSE: VIKRAMTH) had a P/E of 22.8× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 31% below their 52-week high. Its ROCE of 32% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 6.4% and 32% a year over 3 years. It has almost no debt, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹1,001 Cr, ranked 72nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 84% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹322.20
Day high: ₹333.85
Day low: ₹310.00
Prev. close: ₹328.20
Volume: 25.9K

Health check

4 good · 1 fair · 1 to check

ReturnsAhead
+83.7% over a year, better than 6 of 7 peers.
Price tagCheaper
P/E 22.8 vs industry 28.7.
GrowthSteady
Sales +6.4%, profit +31.5% a year over 3 years.
ProfitabilityStrong
ROCE 32.4% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 7 of 9.
Red flags1 to check
31% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,001 Cr, #72 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹154 Cr · profit ₹46 Cr

Market cap: ₹1,001 Cr; Small cap
P/E: 22.8; Industry 28.7
Price to book: 5.57; Peers 4.99
Dividend yield: 0.39%
ROE: 29.2%; Peers 14.7%
ROCE: 32.4%; Peers 17.9%
Debt to equity: 0.02; Debt ₹4.49 Cr
EPS (TTM): ₹13.99
OPM (TTM): 42.0%; Net margin 30.0%
Sales growth: +32.4%; Latest quarter vs a year ago
Profit growth: +67.2%; Latest quarter vs a year ago
Price to sales: 6.48; EV/EBITDA 14.7

Strengths

Return on equity of 29.2%.
Return on capital employed of 32.4%.
Practically debt-free.
Quarterly profit up 67.2% on a year ago.
Quarterly sales up 32.4% on a year ago.

Risks to check

31% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Vikram Thermo (India)

Vikram Thermo (India) Limited engages in the manufacture, marketing, and export of pharmaceutical excipients and chemicals in India and internationally. The company offers pharmaceutical polymer products, such as DRUGCOAT, a methacrylic co-polymer-based pharma polymer used for enteric and protective coating, taste masking, and sustained release formulation; DRCOAT, film coating systems for tablets, capsules, and pellets; AQUAPOL, a rheology modifiers for…

Headquarters: Ahmedabad
Employees: 153
Sector: Healthcare
ISIN: INE337E01010
Website: vikramthermo.com

Price range

52 weeks

₹133.20₹464.70

Today

₹310.00₹333.85

Avg volume (3M): 34.1K
1-year return: plus 83.7%
From 52-week high: minus 31.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
VIKRAMTHVikram Thermo (India)	319.35	minus 2.70%	1,001	22.8	5.57	32.4%	27.7%	42.0%	6.4%	31.5%	0.39%	plus 83.7%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
28.6	34.6	34	37.8	37.9
17.3	19.1	18.9	25.8	19.9
11.3	15.5	15.1	12	18
39.5%	44.7%	44.5%	31.7%	47.6%
0.2	0.2	0.5	0.9	0.9
0.1	0.1	0.1	0.1	0.1
0.7	0.7	0.8	0.8	0.9
10.7	14.9	14.7	12	17.9
25.5%	25.5%	25.4%	29.1%	25.8%
7.9	11.1	11	8.5	13.3
2.53	3.53	3.50	2.72	4.24

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +6.4%
Profit CAGR 3Y: +31.5%
EPS CAGR 3Y: +31.6%
ROE: 29.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
110	100	125	133
–	minus 9.3%	+24.8%	+6.4%
83.6	62.8	79	78.8
26.8	37.4	46	54
24.3%	37.3%	36.8%	40.7%
0.3	−0.2	0.4	0.8
1.1	1	0.7	0.3
3.2	2.4	2.6	3
0.2	1	1	0.6
23	34.7	44.1	52.2
26.6%	25.0%	23.5%	26.3%
16.9	25.4	8.1	38.5
–	+50.1%	minus 68.1%	+375.4%
5.39	8.09	2.58	12.28

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
31.4	31.4	31.4	31.4
58.3	82.2	90.1	126
18.5	7	6.4	4.6
19	22.1	18	26.4
127	143	146	188
64.7	66.1	83	91.1
4.1	4.6	38	33.7
1.1	0.5	0.2	11.8
14.5	2.9	0.2	25
42.9	68.5	24.6	26.4
127	143	146	188

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.1	23.2	23.6	51.6
−12.6	−9.4	−22.4	−41.5
1.5	−14.2	−4	−5.4
1.9	−0.4	−2.7	4.7
−12.8	−6.8	−40.8	−9.7
0.3	16.4	−17.2	41.8
−0.9	−1.6	−2.4	−3.1

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you